Protagonist Therapeutics Reports Granting of Inducement Awards
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protagonist Therapeutics (Nasdaq:PTGX) granted inducement awards on April 15, 2026 to two newly hired employees under its Amended and Restated Inducement Plan.
The awards total options for 55,425 shares and RSUs for 14,425 shares; option exercise price is $105.44, equal to the April 15, 2026 closing price. Vesting spans four years. Awards were approved by the compensation committee and granted in accordance with Nasdaq Rule 5635(c)(4).
Details
News Market Reaction – PTGX
On Apr 17, the first trading day after this news, PTGX closed 2.17% above the previous close.
Data tracked by StockTitan Argus for the Apr 17 session.
Key Figures
- Inducement options
- 55,425 shares
- Aggregate options granted to two new employees under inducement plan
- Inducement RSUs
- 14,425 shares
- Aggregate restricted stock units granted to two new employees
- Option exercise price
- $105.44
- Per-share closing price on Nasdaq Global Market on April 15, 2026
- Option vesting period
- 4 years
- 25% after one year; remainder in equal monthly installments over three years
- RSU vesting period
- 4 years
- One-fourth of RSU shares vest annually
- Plan adoption date
- May 29, 2018
- Original adoption of Amended and Restated Inducement Plan
- Plan amendments
- Feb 18, 2020; Feb 15, 2022
- Dates the inducement plan was amended
- 24h price change
- 0.69%
- Move in PTGX share price prior to this announcement
Historical Context
-
FDA approved ICOTYDE for plaque psoriasis with milestones and royalties owed.
-
FDA accepted rusfertide NDA and granted Priority Review for polycythemia vera.
-
2025 revenue declined and net loss reported despite strong cash position.
-
Detailed 2025 financials with lower collaboration revenue and notable net loss.
-
CEO scheduled to present at multiple investment bank conferences in March.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
rsus financial
exercise price financial
nasdaq global market regulatory
inducement plan financial
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
The new employees received, in the aggregate, options to purchase 55,425 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 14,425 shares of Protagonist Therapeutics common stock. The exercise price of the options is
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. The Company's proprietary peptide technology platform enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra) is approved in the U.S. for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor (IL-23R) licensed to Janssen Biotech, Inc., a Johnson & Johnson company. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. An NDA for rusfertide, a first-in-class hepcidin mimetic peptide that is being co-developed with Takeda Pharmaceuticals pursuant to a worldwide license and collaboration agreement entered in 2024, is under priority review with the FDA. Protagonist holds an option to co-commercialize rusfertide in the U.S. through a 50/50 profit and loss share structure or can opt-out of this structure. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets including an oral IL-17 peptide antagonist, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.